Home › Funds › WAYCROSS PARTNERS, LLC › GILD
WAYCROSS PARTNERS, LLC position in GILD
GILEAD SCIENCES INC · Health Care
WAYCROSS PARTNERS, LLC reported holding 5,732 shares of GILD (GILEAD SCIENCES INC) in its Q2 2026 13F filing — a position valued at US$724K, representing 0.06% of its reported portfolio and ranking #38 among its reported holdings. WAYCROSS PARTNERS, LLC has disclosed GILD holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How WAYCROSS PARTNERS, LLC's GILD position evolved
WAYCROSS PARTNERS, LLC first disclosed a stake in GILD in Q2 2025 at 5,732 shares (US$636K). The position peaked in Q1 2026 at 5,732 shares, worth US$799K. Across 5 filings, WAYCROSS PARTNERS, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 5,732 shares valued at US$724K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 5.73K | $635.51K | New |
| Q3 2025 | 5.73K | $636.25K | Hold |
| Q4 2025 | 5.73K | $703.55K | Hold |
| Q1 2026 | 5.73K | $798.87K | Hold |
| Q2 2026 | 5.73K | $724.18K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 35 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 66.87M sh · $8.45B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Invesco Ltd 39.82M sh · $5.03B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
More on WAYCROSS PARTNERS, LLC
FAQ
How long has WAYCROSS PARTNERS, LLC held GILD?
WAYCROSS PARTNERS, LLC has disclosed GILD holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is WAYCROSS PARTNERS, LLC's current position in GILD?
As of Q2 2026, WAYCROSS PARTNERS, LLC holds 5.73K shares of GILD (GILEAD SCIENCES INC), valued at $724.18K, representing 0.06% of its reported portfolio and ranking #38.
Has WAYCROSS PARTNERS, LLC been buying or selling GILD?
In the latest 13F filing (Q2 2026), WAYCROSS PARTNERS, LLC held unchanged its position in GILD. The position peaked in Q1 2026 at 5.73K shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.